Environmental

Dexcom’s high R&D intensity supports product efficiency and sensor innovation, which can reduce waste per unit of clinical value versus less technology-intensive peers.

The company’s diabetes-device model is less emissions-intensive than heavy manufacturing peers, limiting direct environmental exposure and lowering transition-risk sensitivity.

No major environmental controversies are evident in the provided data, suggesting a cleaner risk profile than peers with larger manufacturing footprints or hazardous-material exposure.

Environmental performance is still constrained by electronics supply-chain and packaging impacts, but these appear manageable relative to broader medtech peers.

Social

Dexcom’s continuous glucose monitoring products directly support chronic-disease management, giving it a stronger patient-benefit profile than peers with less outcome-linked devices.

High gross margin and sustained R&D spending indicate capacity to maintain product quality and user support, which is important for trust in connected medical devices.

Stock-based compensation remains moderate relative to revenue, suggesting less employee-dilution pressure than many growth-stage medtech peers and supporting retention.

The main social risk is product reliability and data usability, but the provided metrics imply a disciplined operating model relative to peers.

Governance

Debt-to-equity and net debt-to-EBITDA are both modest, indicating conservative balance-sheet governance versus more levered medtech peers.

R&D spending at roughly 12.4% of revenue shows management prioritizes long-term product development, which is typically favorable for governance quality in innovation-led healthcare.

Stock-based compensation at about 3.5% of revenue is contained, reducing the risk of excessive dilution compared with peers that rely more heavily on equity pay.

Governance is not top-tier because the available data do not show board independence, audit quality, or controversy resolution, limiting confidence versus best-in-class peers.

Overall Score

DXCM screens as a strong ESG name versus peers, led by a favorable social profile and disciplined capital allocation with limited environmental intensity.

Score Driver: Strong Social Positioning From Patient-Centered Diabetes Technology Relative To Peers.